Clinical Report: VA DOD Updates Asthma Framework

Overview

The updated VA/DoD asthma guidelines emphasize anti-inflammatory strategies and recommend inhaled corticosteroid (ICS)-containing reliever therapies. Evidence from randomized trials indicates that single-device maintenance and reliever therapy significantly reduces severe asthma exacerbations.

Background

Asthma affects approximately 8.7% of US adults, with higher prevalence in certain demographics. The management of asthma has historically relied on short-acting beta-agonists (SABAs) for symptom relief, which has been linked to increased morbidity and mortality. The new guidelines aim to improve asthma control through evidence-based recommendations and a shift towards ICS as a primary treatment.

Data Highlights

Across randomized trials involving nearly 22,000 participants, single-device maintenance and reliever therapy reduced severe asthma exacerbations by about one-third.

Key Findings

• The 2025 VA/DoD guidelines recommend ICS for all asthma patients, regardless of symptom frequency.
• Short-acting beta-agonist (SABA)-only reliever therapy is no longer recommended.
• ICS combined with rapid-onset LABA (formoterol) is suggested for patients aged 12 years or older.
• Step-down therapy is appropriate after at least 3 months of stable control, but ICS should not be discontinued.
• Management of comorbid conditions, such as obesity and gastroesophageal reflux disease, is emphasized for better asthma control.

Clinical Implications

Primary care clinicians should adopt the new guidelines to enhance asthma management, focusing on ICS-containing therapies. The shift towards anti-inflammatory strategies may improve patient outcomes and reduce exacerbations.

Conclusion

The 2025 VA/DoD asthma guidelines represent a significant advancement in asthma management, promoting a unified approach to treatment that prioritizes anti-inflammatory therapies.

References

1. VA/DOD CLINICAL PRACTICE GUIDELINE FOR THE PRIMARY CARE MANAGEMENT OF ASTHMA, 2025 -- VA/DoD Asthma Guidelines
2. Drugs - Real World Outcomes, 2022 -- Incidence of Adverse Drug Reactions from Common Asthma Treatments in Hospitalized Pediatric Patients in the US, 2000–2016
3. Drug Safety, 2019 -- Investigation of Safety Signals for Pediatric Asthma Medications Utilizing the EudraVigilance Spontaneous Reporting Database
4. American Journal of Epidemiology, 2022 -- Replicating Randomized Trials through Observational Database Research: Insights from the RCT-DUPLICATE Project in Asthma and COPD
5. GINA 2025 Global Strategy for Asthma Management, 2025 -- GINA 2025 Strategy Report
6. The New Gastroenterologist — Updated Clinical Guidelines on Eosinophilic Esophagitis Incorporate Recent Advances from the Past Decade
7. VA/DOD CLINICAL PRACTICE GUIDELINE FOR THE PRIMARY CARE MANAGEMENT OF ASTHMA
8. GINA 2025 Global Strategy for Asthma Management an